Severe hypoglycemia identifies vulnerable patients with type 2 diabetes at risk for premature death and all-site cancer: The Hong Kong Diabetes Registry

Diabetes Care

Volumn 37, Issue 4, 2014, Pages 1024-1031

  Kong, Alice P S ^a   Yang, Xilin ^a,b   Luk, Andrea ^a   Ma, Ronald C W ^a   So, Wing Yee ^a   Ozaki, Risa ^a   Ting, Rose ^a   Cheung, Kitty ^a   Ho, Chung Shun ^a   Chan, Michael H M ^a   Chow, Chun Chung ^a   Chan, Juliana C N ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ALBUMINURIA; ARTICLE; BODY MASS; CANCER INCIDENCE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE DURATION; DISEASE REGISTRY; DISEASE SEVERITY; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HONG KONG; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTIVE VALUE; PREMATURE MORTALITY; PROGNOSIS; SYSTOLIC BLOOD PRESSURE; CHEMICALLY INDUCED; COMPLICATION; DIABETES MELLITUS, TYPE 2; EPIDEMIOLOGY; MIDDLE AGED; MORTALITY; NEOPLASMS; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

AGED; DIABETES MELLITUS, TYPE 2; FEMALE; HONG KONG; HUMANS; HYPOGLYCEMIA; MALE; MIDDLE AGED; MORTALITY, PREMATURE; NEOPLASMS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84897823556     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-2507     Document Type: Article

References (37)

1. Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829-840
2. Zoungas S, Patel A, Chalmers J, et al.; ADVANCE Collaborative Group. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010;363:1410-1418
3. Gerstein HC, Miller ME, Byington RP, et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559
4. Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010;340:b4909
5. Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care 2010;33:1389-1394
6. Moen MF, Zhan M, Hsu VD, et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol 2009;4:1121-1127
7. So WY, Chan JC, Yeung VT, et al. Sulphonylurea-induced hypoglycaemia in institutionalized elderly in Hong Kong. Diabet Med 2002;19:966-968
8. Pozzilli P, Leslie RD, Chan J, et al. The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach. Diabetes Metab Res Rev 2010;26:239-244
9. Inzucchi SE, Bergenstal RM, Buse JB, et al.; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-1379
10. Seshasai SR, Kaptoge S, Thompson A, et al.; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011;364:829-841
11. Yang X, So W, Ko GT, et al. Independent associations between low-density lipoprotein cholesterol and cancer among patients with type 2 diabetes mellitus. CMAJ 2008;179:427-437
12. Kong AP, Yang X, Ko GT, et al. Effects of treatment targets on subsequent cardiovascular events in Chinese patients with type 2 diabetes. Diabetes Care 2007;30:953-959
13. Piwernetz K, Home PD, Snorgaard O, Antsiferov M, Staehr-Johansen K, Krans M; The DIABCARE Monitoring Group of the St. Vincent Declaration Steering Committee. Monitoring the targets of the St. Vincent Declaration and the implementation of quality management in diabetes care: the DIABCARE initiative. Diabet Med 1993;10:371-377
14. Yang X, So WY, Tong PC, et al. Development and validation of an all-cause mortality risk score in type 2 diabetes: The Hong Kong Diabetes Registry. Arch Intern Med 2008;168:451-457
15. Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 2006;17:2937-2944
16. Yang X, Ko GT, So WY, et al. Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes 2010;59:1254-1260
17. Yang X, So WY, Ma RC, et al. Low LDL cholesterol, albuminuria, and statins for the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes Care 2009;32:1826-1832
18. Yang X, So WY, Ma RC, et al. Synergistic effects of low LDL cholesterol with other factors for the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry. Acta Diabetol 2012;49(Suppl. 1):S185-S193
19. Yang X, So WY, Ma RC, et al. Low HDL cholesterol, metformin use, and cancer risk in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes Care 2011;34:375-380
20. Yang X, So WY, Ma RC, et al. Predicting values of lipids and white blood cell count for all-site cancer in type 2 diabetes. Endocr Relat Cancer 2008;15:597-607
21. Lin DY, Wei LJ, Ying Z. Checking the Coxmodel with cumulative sums of martingale-based residuals. Biometrika 1993;80:557-572
22. Yang X, So WY, Ma RC, Kong AP, Xu G, Chan JC. Diabetes and cancer: the mechanistic implications of epidemiological analyses from the Hong Kong Diabetes Registry. Diabetes Metab Res Rev 2012;28:379-387
23. Yang X, Ma RC, So WY, et al. Low triglyceride and nonuse of statins is associated with cancer in type 2 diabetes mellitus: the Hong Kong Diabetes Registry. Cancer 2011;117:862-871
24. Pischon T, Boeing H, Hoffmann K, et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med 2008;359:2105-2120
25. Stengel B. Chronic kidney disease and cancer: a troubling connection. J Nephrol 2010;23:253-262
26. Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V. Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care 2003;26:1485-1489
27. Goto A, Arah OA, Goto M, Terauchi Y, Noda M. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ 2013;347:f4533
28. Wright RJ, Frier BM. Vascular disease and diabetes: is hypoglycaemia an aggravating factor? Diabetes Metab Res Rev 2008;24:353-363
29. Gerstein HC, Bosch J, Dagenais GR, et al.; ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia.N Engl J Med 2012;367:319-328
30. So WY, Yang X, Ma RC, et al. Risk factors in V-shaped risk associations with all-cause mortality in type 2 diabetes - The Hong Kong Diabetes Registry. Diabetes Metab Res Rev 2008;24:238-246
31. Kong AP, Chan JC. Cancer risk in type 2 diabetes. Curr Diab Rep 2012;12:325-328
32. Yang X, So WY, Ma RC, Kong AP, Xu G, Chan JC. Diabetes and cancer: the mechanistic implications of epidemiological analyses from the Hong Kong Diabetes Registry. Diabetes Metab Res Rev 2012;28:379-387
33. Katon WJ, Young BA, Russo J, et al. Association of depression with increased risk of severe hypoglycemic episodes in patients with diabetes. Ann Fam Med 2013;11:245-250
34. Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records.Am Heart J 2004;148:99-104
35. Birman-Deych E, Waterman AD, Yan Y, Nilasena DS, Radford MJ, Gage BF. Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Med Care 2005;43:480-485
36. Yang XL, Ma RC, So WY, Kong AP, Xu G, Chan JC. Addressing different biases in analysing drug use on cancer risk in diabetes in nonclinical trial settings - what, why and how? Diabetes Obes Metab 2012;14:579-585
37. Yang X, Wang Y, Luk AO, et al. Enhancers and attenuators of risk associations of chronic hepatitis B virus infection with hepatocellular carcinoma in type 2 diabetes. Endocr Relat Cancer 2013;20:161-171